Bausch Health Companies (NYSE:BHC) Raised to Sell at ValuEngine

ValuEngine upgraded shares of Bausch Health Companies (NYSE:BHC) from a strong sell rating to a sell rating in a report published on Tuesday, ValuEngine reports.

A number of other brokerages also recently weighed in on BHC. Barclays lifted their target price on shares of Bausch Health Companies from $28.00 to $29.00 and gave the stock an overweight rating in a research note on Monday, October 26th. Piper Sandler decreased their price target on shares of Bausch Health Companies from $26.00 to $25.00 and set an overweight rating for the company in a research note on Thursday, November 5th. HC Wainwright reaffirmed a buy rating and issued a $50.00 price target (down from $64.00) on shares of Bausch Health Companies in a research note on Monday, August 24th. Zacks Investment Research downgraded shares of Bausch Health Companies from a hold rating to a strong sell rating and set a $15.00 price target for the company. in a research note on Tuesday, October 13th. Finally, Wells Fargo & Company decreased their price target on shares of Bausch Health Companies from $18.00 to $17.00 and set an equal weight rating for the company in a research note on Wednesday, October 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $28.88.

Shares of NYSE:BHC opened at $18.94 on Tuesday. The firm has a market cap of $6.73 billion, a PE ratio of -3.48, a price-to-earnings-growth ratio of 2.20 and a beta of 1.42. The firm’s fifty day moving average is $16.84 and its 200-day moving average is $17.46. The company has a debt-to-equity ratio of 37.16, a quick ratio of 0.94 and a current ratio of 1.20. Bausch Health Companies has a 52 week low of $11.15 and a 52 week high of $31.97.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Sunday, November 8th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.30. Bausch Health Companies had a negative net margin of 23.92% and a positive return on equity of 173.20%. The business had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter last year, the firm earned $1.21 earnings per share. Bausch Health Companies’s quarterly revenue was down 3.2% on a year-over-year basis. Sell-side analysts forecast that Bausch Health Companies will post 3.72 EPS for the current year.

In related news, insider William D. Humphries sold 5,667 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $16.17, for a total transaction of $91,635.39. Following the sale, the insider now owns 235,035 shares of the company’s stock, valued at approximately $3,800,515.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.14% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Winslow Evans & Crocker Inc. bought a new stake in Bausch Health Companies during the 2nd quarter worth approximately $27,000. Heritage Wealth Advisors bought a new position in shares of Bausch Health Companies in the 3rd quarter worth $31,000. Banque Cantonale Vaudoise bought a new position in shares of Bausch Health Companies in the 3rd quarter worth $37,000. Parallel Advisors LLC increased its holdings in shares of Bausch Health Companies by 3,094.8% in the 2nd quarter. Parallel Advisors LLC now owns 2,460 shares of the company’s stock worth $44,000 after buying an additional 2,383 shares during the last quarter. Finally, JFS Wealth Advisors LLC bought a new position in shares of Bausch Health Companies in the 2nd quarter worth $53,000. 64.46% of the stock is currently owned by institutional investors and hedge funds.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: What are high-yield dividend stocks?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit